Jefferson University Hospitals

Physician Profile

Mary Van Den Berg-Wolf, MD

Jefferson University Physician

Academic Title: Associate Professor

Specialties
Acupuncture
Internal Medicine
Primary Care Physician

Appointment Scheduling

Call 1-800-JEFF-NOW

Existing Patients

Jefferson Health MyChart

Log in to MyChart and schedule an appointment online.

New Patients  | Online Scheduling

New patients can use Online Scheduling to view available appointment times and schedule directly.


Call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Bala Cynwyd
225 E. City Avenue
Suite 109
Bala Cynwyd PA 19004
Phone: (215) 503-3838
Fax: (610) 664-0827

Medical Services

Years in Practice

32

Board Certifications

  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Regional Top Doctor, Castle-Connelly 2015,2014,2013

Clinical Practice Award American College of Physicians, PA Chapter 2012

Fellow of the Philadelphia College of Physicians

Fellow of the American College of Physicians

Notes

Areas of interest include Primary Care, Internal Medicine, patients with musculoskeletal issues and injuries, Medical acupuncture for cancer patients, Medical Acupuncture including facial rejuvenation acupuncture and Chinese Scalp Acupuncture for neurologic conditions.

Education

  • Georgetown University School of Medicine, Medical School

Internship

  • Temple University Hospital

Residency

  • Temple University Hospital
  • Vrij Universiteit Medical Center - VUMC, Amsterdam

Recent Publications

Reducing False-Positive HIV Diagnosis in Niger: A Women's Issue

Acupuncture is more than placebo treatment

Electronic cigarettes: A perspective for the primary care physician

Elevated testosterone levels in HIV-infected men: Case report and a retrospective chart review

HIV-infected man who presents for preoperative evaluation

Sadness in the SUN: Using computerized screening to analyze correlates of depression and adherence in HIV-infected adults in the united states

Minority HIV patients' perceptions of barriers and facilitators to participation in clinical research

Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial

Immune reconstitution inflammatory syndrome (IRIS) manifesting as anogenital HSV-2 infection in a HIV-1-infected patient after initiation of raltegravir

Therapeutic Strategies for Chronic Hepatitis B Virus Infection in 2008-Optimum Dosing Lamivudine Challenged for HIV-1 Infected Patients

Preoperative cardiac evaluation for noncardiac surgery: A critical review

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of Efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons

Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients

Ethnicity, race, and gender: Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST study)

The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

Elevations in creatine kinase and hepatic transaminases in an HIV-positive patient

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy

Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial